Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

2.

Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes.

Shimada T, Takenaka S, Murayama N, Yamazaki H, Kim JH, Kim D, Yoshimoto FK, Guengerich FP, Komori M.

Chem Res Toxicol. 2015 Feb 16;28(2):268-78.

3.

Binding free energies for nicotine analogs inhibiting cytochrome P450 2A6 by a combined use of molecular dynamics simulations and QM/MM-PBSA calculations.

Lu H, Huang X, AbdulHameed MD, Zhan CG.

Bioorg Med Chem. 2014 Apr 1;22(7):2149-56. doi: 10.1016/j.bmc.2014.02.037. Epub 2014 Mar 3.

4.

Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.

Tiong KH, Mohammed Yunus NA, Yiap BC, Tan EL, Ismail R, Ong CE.

PLoS One. 2014 Jan 27;9(1):e86230. doi: 10.1371/journal.pone.0086230. eCollection 2014.

5.

Contributions of human enzymes in carcinogen metabolism.

Rendic S, Guengerich FP.

Chem Res Toxicol. 2012 Jul 16;25(7):1316-83. doi: 10.1021/tx300132k. Epub 2012 May 10. Review.

6.

Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo.

Ueng YF, Chen CC, Chung YT, Liu TY, Chang YP, Lo WS, Murayama N, Yamazaki H, Souček P, Chau GY, Chi CW, Chen RM, Li DT.

Br J Pharmacol. 2011 Jul;163(6):1250-62. doi: 10.1111/j.1476-5381.2011.01341.x.

7.

Genetics of tobacco use.

Maserejian NN, Zavras AI.

Tob Induc Dis. 2004 Jun 15;2(2):81-102. doi: 10.1186/1617-9625-2-2-81.

8.

Nicotinic receptors containing the alpha7 subunit: a model for rational drug design.

Sharma G, Vijayaraghavan S.

Curr Med Chem. 2008;15(28):2921-32. Review.

9.

Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ.

Br J Clin Pharmacol. 1993 Dec;36(6):521-30.

10.
11.
12.

Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6.

Kinonen T, Pasanen M, Gynther J, Poso A, Järvinen T, Alhava E, Juvonen RO.

Br J Pharmacol. 1995 Nov;116(6):2625-30.

13.

Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.

Andersson T, Miners JO, Veronese ME, Birkett DJ.

Br J Clin Pharmacol. 1994 Aug;38(2):131-7.

14.

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

Andersson T, Miners JO, Veronese ME, Birkett DJ.

Br J Clin Pharmacol. 1994 Jun;37(6):597-604.

15.

Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.

Daly AK, Cholerton S, Armstrong M, Idle JR.

Environ Health Perspect. 1994 Nov;102 Suppl 9:55-61.

16.

A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.

Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR, et al.

Am J Hum Genet. 1995 Sep;57(3):651-60.

17.

Elucidation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology.

Guengerich FP, Shimada T, Raney KD, Yun CH, Meyer DJ, Ketterer B, Harris TM, Groopman JD, Kadlubar FF.

Environ Health Perspect. 1992 Nov;98:75-80.

Supplemental Content

Support Center